Navigation Links
GeneGo Receives SBIR Grant

ST. JOSEPH, Mich., Jan. 12 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today they have been awarded a $336K Phase I SBIR grant from the NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES for creating a novel type of predictive signatures for drug resistance. Under this project GeneGo will develop "regulation signatures" which should overcome many shortcomings of existing methods of molecular diagnostics. For this work GeneGo will utilize its extensive, manually-curated database of signaling interactions and recently developed algorithms for identifying key proteins in signaling networks. The work will be performed in collaboration with the Van Andel Institute for Translational Medicine.  

"What we propose here is the novel concept of using inferred activity of key signaling proteins for building predictive models. Our early results indicate that such models should be significantly more robust than currently available diagnostic applications which are based directly on gene or protein levels. We are very excited about the opportunity provided by NIH support to further develop and validate this approach. If successful, the methodology could be replicated for developing predictive models for sensitivity to a broad range of targeted therapies, leading to a number of diagnostic applications such as specialized molecular tests, systems for formulating combination therapies and procedures for selecting patient cohorts for clinical trials," said Andrej Bugrim, GeneGo COO and PI on the grant.

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscoveryplatform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.0, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.0 is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.

For more information, please visit the company's web site at

SOURCE GeneGo, Inc.



SOURCE GeneGo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
2. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
3. VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
4. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
5. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Gram-Negative Bloodstream Pathogens
6. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
7. The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign
8. BASFs Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label
9. CareCentrix Receives URAC Health Utilization Management Accreditation
10. Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
11. SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System
Post Your Comments:
(Date:11/30/2015)...  Kevin Smith has been appointed Chief Commercial ... in wireless monitoring of vital signs.  As CCO ... Mr. Smith will be responsible for the development ... will also directly oversee partnering with US hospitals ... SensiumVitals, the first early warning detection device to ...
(Date:11/30/2015)... LAKE, N.J. and SAN DIEGO ... and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... has accepted for filing the New Drug Application (NDA) ... the extended release formulation will offer patients a chronic ... ® ) is currently approved as an ...
(Date:11/30/2015)... 30, 2015 iCAD, Inc. (Nasdaq: ... its latest solutions for advanced image analysis and ... at the Radiological Society of North American (RSNA) ... from November 29 to December 4, 2015. ... iReveal®, an automated breast density assessment solution, PowerLook® ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone ... member, close friend, or animal pass away, death lives among us. It is your ... Coming from a family of 11 children, author T Sky understands that she may ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that they are showcasing ... dentists to make complex business decisions by providing the tools and information they need ... survey with 10 procedures customized by zip code. , The Sikka Software Ecosystem ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in the US ... is a long-term resorbable surgical mesh intended to support and reinforce soft tissue ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... be of critical importance to the medical schools of the future. To reach ... healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by the American ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... a leading provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced ... Microsoft Partner Program with competencies in the Application Development, demonstrating a “best-in-class” ...
Breaking Medicine News(10 mins):